Advertisement
AMGN vs BIIB
Which Stock Would AI Choose? Amgen (AMGN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- Both AMGN and BIIB have delivered strong share-price gains in recent months, but their fundamental stories diverge sharply: Amgen is compounding on established momentum, while Biogen is navigating a growth reset.
- Amgen offers a diversified product base, double-digit revenue growth, and a rising dividend, whereas Biogen leans on a fast-growing "growth portfolio" while absorbing declines in its legacy multiple sclerosis (MS) franchise.
- Amgen's relative performance has been steadier and less volatile, supported by positive late-stage clinical data and consistent earnings beats; Biogen's results, by contrast, have been mixed with reported losses tied to acquisition-related charges.
- Tickeron AI Verdict: Based on trend consistency, stability, and relative positioning, Tickeron's AI would currently favor AMGN over BIIB.
- For deeper detail, explore AMGN Major News and AMGN Today's Price Move, plus BIIB Major News and BIIB Today's Price Move.
- To see which automated strategies are currently aligned with market conditions, browse the Trending AI Robots.
Introduction
Amgen Inc. (AMGN) and Biogen Inc. (BIIB) are two of the most closely followed large-cap biotechnology names, yet they sit at very different stages of their corporate lifecycles. This stock comparison is relevant for investors weighing a mature, diversified pharmaceutical engine against a company attempting a high-stakes turnaround. Both stocks have posted comparable year-to-date gains in recent market activity, which makes the question of relative performance particularly timely. Growth-oriented traders may be drawn to Biogen's expanding pipeline readouts, while stability-seeking investors may favor Amgen's broader portfolio and income stream. Understanding how each company's market positioning has shifted in recent weeks provides a clearer framework for evaluating which stock may currently hold the edge.
AMGN Overview and Recent Performance
Amgen is a global biotechnology leader headquartered in Thousand Oaks, California, with a portfolio spanning inflammation, oncology, bone health, cardiovascular disease, and rare disease. The company generates roughly $38 billion in trailing revenue and carries a market capitalization near $252 billion, making it one of the sector's largest players.
Recent stock behavior has been notably strong. Shares have climbed more than 40% year to date and roughly 60% over the trailing one-year period, outpacing the broader market. The rally has been reinforced by positive Phase 3 data for IMDELLTRA in extensive-stage small cell lung cancer and for Tezspire in eosinophilic esophagitis, as well as analyst upgrades to near-term earnings expectations. Amgen has also beaten consensus earnings estimates (EPS, or earnings per share) in recent consecutive quarters, with revenue growing about 10% year over year in its latest reported period.
Sentiment has been further supported by a stable dividend, which yields above 2%, and a relatively low beta of about 0.41, indicating lower-than-market volatility. Investors are also watching the experimental obesity therapy MariTide, a GLP-1 (glucagon-like peptide-1) candidate in Phase 3 trials. The main headwinds are patent expirations on legacy products such as Prolia/denosumab, Enbrel, and Otezla, which face biosimilar and pricing pressure.
BIIB Overview and Recent Performance
Biogen is a Cambridge, Massachusetts-based biotechnology company historically defined by its neuroscience franchise, particularly treatments for multiple sclerosis. In recent years the company has repositioned around a "growth portfolio" spanning Alzheimer's disease, rare disease, and specialized immunology.
In its most recent quarter, Biogen reported total revenue of approximately $2.8 billion, up 11% year over year, with adjusted EPS of $2.62 that comfortably exceeded consensus estimates. The growth portfolio advanced about 49% to $1.26 billion, led by LEQEMBI (Alzheimer's), SPINRAZA, SKYCLARYS, and the newly acquired SYFOVRE and EMPAVELI from the Apellis transaction that closed in May 2026. Management raised the lower end of its full-year earnings guidance, signaling confidence in the integration.
However, the picture is more complex beneath the surface. Biogen swung to a reported (GAAP, or generally accepted accounting principles) net loss in its latest quarter, driven by acquired in-process research and development (IPR&D) charges and milestone expenses. Legacy MS product revenue declined 13% amid competitive pressure, and operating expenses rose sharply. Shares have gained about 44% year to date but have been more volatile, with notable single-session pullbacks following earnings. Near-term catalysts include December readouts for the lupus candidate litifilimab.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each engineered with its own trading style, strategy, timeframe, performance history, and statistical profile. Because market conditions change constantly, only a subset of these bots are well-suited to the current environment at any given moment. The Trending AI Robots page curates that smaller group, highlighting the strategies whose recent performance and positioning align most closely with prevailing market dynamics. Traders can review each bot's tracked statistics, trade frequency, and historical results before deciding which approaches merit further attention. Exploring this section can help investors identify automated strategies currently showing strength rather than sifting through the full catalog manually.
Head-to-Head Comparison
The two companies differ most clearly in business model and risk profile. Amgen is a diversified, high-revenue operator with multiple billion-dollar products and a consistent free-cash-flow engine that funds both dividends and a broad pipeline. Its challenge is managing a rolling set of patent expirations while scaling newer launches and the MariTide obesity program.
Biogen, by contrast, is a leaner, more concentrated turnaround story. Its recent growth is heavily dependent on a handful of newer products and the Apellis acquisition, while its legacy MS business continues to erode. This creates higher optionality—successful pipeline readouts could drive outsized upside—but also greater earnings volatility, as evidenced by the recent GAAP loss and elevated spending.
On momentum, both stocks have trended higher, but Amgen's advance has been more consistent and less choppy, with lower beta and steadier earnings delivery. On valuation, Amgen trades at a lower forward P/E (price-to-earnings) ratio and pays a dividend, while Biogen offers no comparable yield and carries a richer trailing valuation complicated by one-time charges. Sector exposure also differs: Amgen spans inflammation, oncology, and cardiovascular markets, whereas Biogen remains more exposed to neuroscience and rare disease. In short, Amgen represents stability and breadth, while Biogen represents a higher-risk, catalyst-driven reset.
Tickeron AI Verdict
Weighing trend consistency, stability, and relative positioning, Tickeron's AI would likely favor AMGN in the current environment. Amgen combines a steadier uptrend, lower volatility, recurring earnings beats, and a diversified revenue base with an income component, all of which tend to rank favorably in momentum and stability models. Biogen's story is improving and carries meaningful catalyst potential, but its recent reported losses, rising expenses, and reliance on a still-transitioning product mix introduce more uncertainty. The verdict is probabilistic rather than definitive: if Biogen's upcoming pipeline readouts land favorably, sentiment could shift quickly. For now, however, the observable data points toward Amgen as the more consistent and better-positioned of the two.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and BIIB is a Hold.
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 43 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 28 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 25 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to good earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
Momentum Indicator for BIIB turns positive, indicating new upward trend
BIIB saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 57 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 165 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 20 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 58 cases where BIIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 35 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.947) is normal, around the industry mean (-1.421). P/E Ratio (43.724) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
AMGN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 100 | |
SMR RATING 1..100 | 15 | 84 | |
PRICE GROWTH RATING 1..100 | 9 | 6 | |
P/E GROWTH RATING 1..100 | 33 | 3 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIIB's Valuation (76) in the Biotechnology industry is in the same range as AMGN (79). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (3) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for BIIB (84). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (6) in the Biotechnology industry is in the same range as AMGN (9). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
BIIB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as AMGN (33). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 61% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 59% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 51% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 49% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 65% |
| Advances ODDS (%) | 3 days ago 62% | 3 days ago 60% |
| Declines ODDS (%) | 9 days ago 47% | 9 days ago 67% |
| BollingerBands ODDS (%) | 1 day ago 55% | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while BIIB’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while BIIB’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 4 bearish.
- BIIB’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +0.86% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -0.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.
Reported Earning Dates
AMGN is expected to report earnings on Feb 09, 2027.
BIIB is expected to report earnings on Feb 17, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-1.33% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +0.62% | ||
| PFE - AMGN | 51% Loosely correlated | +0.31% | ||
| GILD - AMGN | 48% Loosely correlated | -0.67% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.37% | ||
| BIIB - AMGN | 47% Loosely correlated | +0.06% | ||
| MRK - AMGN | 47% Loosely correlated | -0.59% | ||
More | ||||
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +0.06% | ||
| AMGN - BIIB | 50% Loosely correlated | +0.62% | ||
| AZN - BIIB | 49% Loosely correlated | -0.69% | ||
| PFE - BIIB | 48% Loosely correlated | +0.31% | ||
| MRK - BIIB | 46% Loosely correlated | -0.59% | ||
| GILD - BIIB | 42% Loosely correlated | -0.67% | ||
More | ||||